Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dolphin Medical ServicesBOM:526504 36 Cyclically Adjusted PS Ratio is 19.68 as of Jul. 30, 2026, which is 304% above its 10-year median of 4.87. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.39 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Dolphin Medical Services ranks worse than 94.81% on this metric.
The historical rank and industry rank for Dolphin Medical Services's Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:526504'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.28 Med: 4.87 Max: 24
Current: 20.98
During the past years, Dolphin Medical Services's highest Cyclically Adjusted PS Ratio was 24.00. The lowest was 1.28. And the median was 4.87.
BOM:526504's Cyclically Adjusted PS Ratio is ranked worse than 94.81% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.88
vs BOM:526504: 20.98
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Dolphin Medical Services's adjusted revenue per share data for the three months ended in Mar. 2026 was ₹0.127. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹0.38 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Dolphin Medical Services (BOM:526504) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Dolphin Medical Services Cyclically Adjusted PS Ratio Related Terms
Dolphin Medical Services Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Dolphin Medical Services's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dolphin Medical Services Cyclically Adjusted PS Ratio Chart
BOM:526504 vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's Cyclically Adjusted PS Ratio falls into.
Dolphin Medical Services Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 19.68 mean?
Dolphin Medical Services (BOM:526504) has a Cyclically Adjusted PS Ratio of 19.68 as of Jul. 30, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dolphin Medical Services and its competitors. This is 304% above median its historical median of 4.87. Over the past decade, Dolphin Medical Services' Cyclically Adjusted PS Ratio has ranged from 1.28 to 24.00. According to the industry distribution chart, Dolphin Medical Services ranks #128 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 94.8%.
Is Dolphin Medical Services' Cyclically Adjusted PS Ratio too high?
Dolphin Medical Services' current Cyclically Adjusted PS Ratio of 19.68 is 304% above median its 10-year median of 4.87. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 24.00. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.88. Dolphin Medical Services' value of 19.68 is 946.8% above this industry median. Based on the distribution chart, Dolphin Medical Services ranks #128 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #128 out of 135 companies for Cyclically Adjusted PS Ratio. This places Dolphin Medical Services in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.88. Dolphin Medical Services' value of 19.68 is 946.8% above this benchmark. Historically, Dolphin Medical Services' own Cyclically Adjusted PS Ratio has ranged from 1.28 to 24.00 over the past decade. While the company's 10-year median is 4.87 vs. the industry median of 1.88, Dolphin Medical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.88, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dolphin Medical Services's current Cyclically Adjusted PS Ratio of 19.68 is 946.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dolphin Medical Services and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current Cyclically Adjusted PS Ratio is 19.68, which is 304% above median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.39, compared to a current price of ₹7.48 — trading 213% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 19.68, which is 304% above median its 10-year median of 4.87 and 946.8% above the Medical Diagnostics & Research industry median of 1.88. Dolphin Medical Services' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current Cyclically Adjusted PS Ratio is 19.68 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹7.48 is trading 213% above its estimated GF Value™ of ₹2.39.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
Cyclically Adjusted PS Ratio: 19.68 (304% above median its 10-year median of 4.87)
GF Value™: ₹2.39 vs. price of ₹7.48 (213% above fair value)
Industry Position: 946.8% above the Medical Diagnostics & Research median (#128 of 135)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score
Get the complete analysis for BOM:526504
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
